CD22-targeted CD28 bispecific antibody enhances antitumor efficacy of odronextamab in refractory diffuse large B cell lymphoma models
Joyce Wei,Welby Montalvo-Ortiz, Lola Yu,Amanda Krasco,Kara Olson,Sahar Rizvi,Nathalie Fiaschi,Sandra Coetzee, Fang Wang,Erica Ullman,Hassan Shakil Ahmed,Evan Herlihy, Ken Lee,Lauren Havel,Terra Potocky,Sarah Ebstein,Davor Frleta, Aditi Khatri,Stephen Godin,Sara Hamon,Jurriaan Brouwer-Visser, Travis Gorenc,Doug MacDonald,Aynur Hermann,Aafia Chaudhry,Andres Sirulnik,William Olson,John Lin,Gavin Thurston,Israel Lowy,Andrew J. Murphy,Eric Smith,Vladimir Jankovic,Matthew A. Sleeman,Dimitris Skokos Science Translational Medicine（2022）
关键词
cd28 bispecific antibody,antitumor efficacy,cell lymphoma,odronextamab
AI 理解论文
溯源树
样例
